Skip to main content
OpenTrials
Completed

NCT Number: NCT00910767

Closing the Loop in Adults With Type 1 Diabetes

The main objective of this study is to evaluate the feasibility of closed loop insulin pump therapy to improve overnight glucose control in adults with type 1 diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Addenbrooke's Hospital

Cambridge, CB2 0QQ, United Kingdom

About this study

People with type 1 diabetes(T1D) need regular insulin injections or continuous delivery of insulin using an insulin pump in order to keep the blood glucose levels normal. We know that keeping blood sugars in the normal range will help prevent long term diabetes related complications involving the eyes, kidneys and heart. However, achieving treatment goals can be very difficult as the tighter we try to control blood glucose levels, the greater the risk of the person developing episodes of low glucose levels (hypoglycaemia). This is a particular problem at night and one solution is to develop a system whereby the amount of insulin injected is very closely matched to the blood sugar levels on a continuous basis. This can be achieved by what is called a "closed loop system" where a small glucose sensor placed under the skin communicates with a computer containing an algorithm that drives an insulin pump. This system is being developed in Cambridge and we have trialed this on 16 children and adolescents with T1D in a clinical setting over the past year. We have found that this system is very effective at preventing hypoglycaemia in this group of patients.

We will recruit 12 adults with T1D on insulin pump therapy, and the studies will be done in a clinical research facility. The subjects will be studied on two nights. On one night they will have their normal insulin pump therapy and on the other night their insulin pump will be varied according to information about blood glucose values from the continuous glucose sensor. This information will be manually typed into the computer every 15 minutes from 8pm until 8am. The algorithm will advise of the insulin infusion rate and this will be manually changed by a trained nurse every 15 minutes throughout the night.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 1 diabetes, as defined by WHO for at least 6 months or confirmed C-peptide negative.
  • On insulin pump therapy for at least 3 months

Exclusion criteria

  • Non-type 1 diabetes mellitus
  • Any physical/psychological disease likely to interfere with the study
  • Taking medication likely to interfere with interpretation of the results
  • Known/suspected allergy against insulin
  • Patients with clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator
  • Ongoing severe recurrent hypoglycaemia as judged by the investigator.

Treatment and study plan

Conventional insulin pump delivery

Device

Subcutaneous delivery of Novorapid insulin according to usual pump regime

Closed Loop

Device

Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings

Primary outcomes

  1. Percentage of plasma glucose values in target (3.9 - 8.0 mmol/L)

    Time frame: 1900 to 0800hr

Secondary outcomes

  1. Percentage of CGM (continuous glucose monitoring) values in target (3.9-8.0 mmol/L)

    Time frame: 1900 to 0800hr

  2. Percentage of plasma glucose and CGM values in target (3.9-8.0 mmol/L)

    Time frame: 0000 to 0800hr

  3. Percentage of plasma glucose and CGM values in target (3.9-8.0 mmol/L)

    Time frame: 0800 to 1200hr

  4. Percentage of plasma glucose and CGM values below 3.9 mmol/L

    Time frame: 1900 to 0800hr

  5. Percentage of plasma glucose and CGM values below 3.9 mmol/L

    Time frame: 0000 to 0800hr

  6. Percentage of plasma glucose and CGM values below 3.9 mmol/L

    Time frame: 0800 to 1200hr

  7. Percentage of plasma glucose and CGM values above 8.0 mmol/L

    Time frame: 1900 to 0800hr

  8. Percentage of plasma glucose and CGM values above 8.0 mmol/L

    Time frame: 0000 to 0800hr

  9. Percentage of plasma glucose and CGM values above 8.0 mmol/L

    Time frame: 0800 to 1200hr

  10. Average plasma and CGM glucose

    Time frame: 1900 to 0800hr

  11. Average plasma and CGM glucose

    Time frame: 0000 to 0800hr

  12. Average plasma and CGM glucose

    Time frame: 0800 to 1200hr

  13. Average plasma insulin concentration

    Time frame: 1900 to 0800hr

  14. Average plasma insulin concentration

    Time frame: 0000 to 0800hr

  15. Average plasma insulin concentration

    Time frame: 0800 to 1200hr

  16. Total dose of insulin administered

    Time frame: 1900 to 0800hr

  17. low blood glucose index (LBGI) score

    Time frame: 1900 to 0800hr

  18. high blood glucose index (HBGI) score

    Time frame: 1900 to 0800hr

  19. low blood glucose index (LBGI) score

    Time frame: 0000 to 0800hr

  20. low blood glucose index (LBGI) score

    Time frame: 0800 to 1200hr

  21. high blood glucose index (HBGI) score

    Time frame: 0000 to 0800hr

  22. high blood glucose index (HBGI) score

    Time frame: 0800 to 1200hr

  23. Percentage of plasma glucose and CGM values below 3.0 mmol/L

    Time frame: 1900 to 0800hr

  24. Percentage of plasma glucose and CGM values below 3.0 mmol/L

    Time frame: 0000 to 0800hr

  25. Percentage of plasma glucose and CGM values below 3.0 mmol/L

    Time frame: 0800 to 1200hr

Sponsors and collaborators

Lead sponsor

University of Cambridge

Other

Collaborators

  • Cambridge University Hospitals NHS Foundation Trust
  • Diabetes UK

Registry information

Official study title

A Randomised, 2-period Cross-over Study to Assess the Feasibility of Overnight Computer-based Glucose Control Based on Continuous Subcutaneous Glucose Monitoring, and Compare it With Conventional Pump Therapy in Adults With Type 1 Diabetes

Acronym: ANGELA01

Important dates

Study start
2009
Primary completion
2009
Study completion
2009
First posted
Jun 1, 2009
Registry last updated
Sep 17, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.